Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Part 1: Why test?

Part 2: How to get biopsies for testing?

Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing

Part 4: Clinical decision making - Interpretation of next generation sequencing results

Screen-detectable cancers account for majority of early-onset cancer cases under age 50

AACR 2026: Latest video and news updates here

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours